WoS İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/6
Browse
5 results
Search Results
Article Novel Hydrazide-Hydrazone Derivatives Containing Flurbiprofen 1,2,4-Triazole as Anticancer Agents: Design, Synthesis and Biological Evaluation(Slovensko Kemijsko Drustvo, 2026) Küçükgüzel, Ş. Güziz; Gökoğlan, Ecem; Yılmaz, Özgür; Çevik, Özge; Çakıcı, Çiğdem; Erdoğan, ÖmerHydrazone derivatives are one of the scaffolds frequently used in new drug development studies. Due to the promising pharmacological effects of the hydrazone structure, fifteen new hydrazide-hydrazone compounds containing flurbiprofen 1,2,4-triazole were synthesized in this study and their in vitro anticancer effects were tested. All compounds were tested for cytotoxic effects against breast cancer cell lines (MCF-7 and MDA-MB231), and glioblastoma cell line (U87) by using MTT assay. Among the synthesized compounds, compounds 7a and 7c exhibited the most potent cytotoxic activity with IC50 values of 7.80 +/- 1.20 & micro;M and 2.40 +/- 0.93 & micro;M against MCF-7 cell line, while compound 7a showed the highest activity with IC50 value of 7.63 +/- 1.05 & micro;M against MDA-MB231 cell line. In addition, compounds 7c and 7n presented cytotoxic activity with IC50 values of 10.31 +/- 4.63 & micro;M and 10.81 +/- 6.11 & micro;M against U87 cell line. The possible cytotoxic effects of compounds on mouse fibroblast cell line (L929) were assessed for their safety and compounds 7a, 7c, and 7n were found less toxic than 5-fluorourasil. Additionally, compound 7c was further studied to investigate its effects on apoptosis and PI3K activity, which play a role in cancer development. The results showed that compound 7c increased apoptosis in MCF-7 cells and it displayed PI3K enzyme inhibitory activity. Our study revealed that the synthesized hydrazone compounds have the potential to be lead compounds for further studies on cancer.Article Exploring E-Health Literacy Levels among Turkish Women Diagnosed with Breast Cancer: A Cross-Sectional Study(BMC, 2026) Akkurt, Burcu; Coskunsu, Dilber Karagozoglu; Reyhanioglu, Duygu Aktar; Simsek, Mine; Tosun, Anil; Yilmaz, Nergis; Koseoglu, AygulAccess to digital health information has increased for women diagnosed with breast cancer; however, searching, understanding, and interpreting this information requires adequate e-health literacy. This study aimed to determine the e-health literacy levels of women diagnosed with breast cancer and to examine the relationship between e-health literacy and selected sociodemographic and clinical characteristics. In addition, women's awareness of e-health and telerehabilitation concepts, as well as their internet use patterns, were evaluated to inform future digital health initiatives. Data were collected through face-to-face and online methods using an Information Form to assess participant characteristics and the E-health Literacy Scale to measure e-health literacy. The study included 336 voluntary Turkish-speaking women aged 18 years and older diagnosed with breast cancer.The median e-health literacy score on the E-health Literacy Scale was 25 (range: 8-40), with a mean score of 24.6 +/- 7.62. E-health literacy levels were significantly associated with age, educational level, time since diagnosis, and awareness of e-health and telerehabilitation concepts (p < .05), with lower scores observed among older women. In multivariable linear regression analysis, these sociodemographic and care-related factors jointly explained approximately 47% of the variance in e-health literacy levels. Overall, the findings indicate that women with breast cancer in Türkiye have limited awareness of e-health and telerehabilitation concepts, and that e-health literacy levels are significantly associated with age, educational level, time since diagnosis, and awareness of telerehabilitation. These results underscore the importance of developing targeted digital health education initiatives and awareness-based interventions to enhance e-health literacy and support equitable access to digital health services among breast cancer survivors.Article Citation - WoS: 2Citation - Scopus: 3Biological Activities of Etodolac-Based Hydrazone, Thiazolidinone and Triazole Derivatives on Breast Cancer Cell Lines MCF-7 and MDA-MB(Wiley, 2025) Sevinc, Sevgi Kocyigit; Cikla-Suzgun, Pelin; Tiber, Pinar Mega; Kucukguzel, S. Guniz; Orun, Oya; Güniz Küçükgüzel, Ş.In this study, several etodolac-based hydrazone, thiazolidinone, and triazole derivatives that we synthesized and characterized in our earlier research were tested against the hormone-responsive breast cell line MCF-7 and the triple-negative MDA-MB-231, as well as the murine origin fibroblast cell line L-929, at varying doses for their effects on cell viability and toxicity and for their inhibitory activity on cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) formation. Cell viability and apoptosis tests were utilized to assess the anti-cancer potential of etodolac and its derivatives after the cells were exposed to varied concentrations of synthesized compounds for three different time periods. ELISA and Western blot methods were used to detect protein levels. All synthesized compounds demonstrated higher anti-cancer activity at significantly lower doses compared to etodolac (half-maximal inhibitory concentration [IC50] of 0-50 mu M range in derivatives versus 0.5-1 mM range in etodolac). Except for SGK 242, which had a major toxic effect on all cells, the chemicals SGK 206 and SGK 217 had a twice-less impact on control murine L-929 fibroblasts. Similar to proliferation, low concentrations of SGK 206 and SGK 217 (25-50 mu M) significantly induced apoptosis in breast cancer cells but not in normal cells. Additionally, they inhibited COX-2 protein expression at 50 mu M, and SGK 206 inhibited PGE2 release more effectively than etodolac in cancer cells. The results of this study suggest that, in comparison to a healthy control group, the thiazolidinone derivative SGK 206 and the thiazolidinone derivative SGK 217 are more effective than etodolac when it comes to the breast cancer cell lines MCF-7 and MDA-MB-231. SGK 206 exhibits a low IC50 value, a distinct dose-response relationship, and strong apoptotic effects, particularly on MDA-MB-231 cells.Article Citation - WoS: 7Effect of Flurbiprofen Derivative (sgk597) on Cell Proliferation and Apoptosis of Breast Cancer Cell Lines(Istanbul Univ, Fac Pharmacy, 2022) Atlihan, Irem; Sevinc, Sevgi Kocyigit; Orun, Oya; Yilmaz, Ozgur; Kucukguzel, S. Guniz; Tiber, Pinar MegaBackground and Aims: The incidence of breast cancer is increasing day by day, especially in women. The search for new drugs against breast cancer is the focus of attention in research. Breast cancer and prostate cancer have remarkable biological similarities. Therefore, the 4-(4-chlorophenyl)-3-(1-(2-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-5-((4-fluorobenzyl)thio)-4H-1,2,4-triazole (SGK597) compound that is suppressing cell proliferation in prostate cancer, was studied in MCF-7 breast can-cer and MCF-10A mammary epithelial cell lines. Methods: The WST-8 method was used to determine cell viability and cytotoxicity of SGK597 in MCF-7 and MCF10-A cell lines. The JC-1 test was applied to determine changes in mitochondrial membrane potential. The protein expression levels of Bax, Bcl-2, and c-PARP associated with apoptosis were determined using Western blot analysis.Results: After 24 and 48 hours of incubation of SGK597, the IC50 values were 28.74 pM and 17.28 pM for MCF-7; 65.9 pM and 50.5 pM for MCF-10A, respectively. Mitochondrial membrane potential showed a tendency toward depolarization in MCF-7 cells as a result of increasing concentration of SGK597, while the same tendency was not seen for MCF-10A. As a result of western blot experiments, no increase in the Bax/Bcl-2 ratio and c-PARP expression level was observed, indicating no apoptosis.Conclusion: It was observed that the compound SGK597 suppressed MCF-7 cell proliferation. These results indicate that SGK597 may be a candidate compound for use as an anticancer agent. Keywords: Apoptosis, breast cancer, flurbiprofen, thioether, triazoleArticle Validity and Reliability of the Symptom-Management Self- Efficacy Scale for Breast Cancer Related To Chemotherapy(Galenos Publ House, 2022) Semiz, Demet; Saglam Aksut, Rabia; Sağlam, RabiaObjective: Since breast cancer (BC) is one of the most common cancer types among women, it is very important for nurses to assess symptom-management and self-efficacy of patients during chemotherapy treatment. This study was carried out to examine the validity and reliability of the symptom-management self-efficacy scale for BC related to chemotherapy. Methods: The study sample of this methodological research consisted of 248 women receiving chemotherapy treatment due to breast cancer in a public hospital in Istanbul between November 2017 ans March 2018. Translation-back translation method was used to assess the language validity of the scale. Kaiser-Mayer-Olkin and Bartlett's tests were applied to evaluate the sampling adequacy and the suitability of the data for factor analysis. Results: The content validity of the Turkish form was 0.912; Cronbach alpha coefficient of the scale was 0.905. The factor loads of all the items belonging to the scale were above 0.40, and explained variance for the scale was as follows; 16,284 for the problem-solving sub-dimension; 13,517 for the sub-dimension of managing problems in emotional and interpersonal relationships, and total explained variance of the scale was found to be 46,944. For this reason, no items were removed from the scale and the scale was accepted as having 3 sub-dimensions as it was in the original. Conclusion: Findings obtained from this study showed that the Turkish version of the scale was valid and reliable and could be used in research and clinical practice in Turkey.